Research
Molecular
Tirzepatide is a GIP receptor and GLP-1 receptor agonist.
Understanding the mechanism can help in predicting the drug's effects and potential interactions.
StrongSupportsmedium confidence
Tirzepatide is a Glucose-dependent Insulinotropic Polypeptide (GIP) receptor and Glucagon-Like Peptide-1 (GLP-1) receptor agonist.
Why this rating
The abstract provides a clear description of the drug's mechanism.
Source
Drug Review: Tirzepatide
Juman Alsaab · Pharmacology Toxicology and Biomedical Reports · 2023
DOI 10.5530/ptb.2023.9.3
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →